company background image
CRSP logo

CRISPR Therapeutics NasdaqGM:CRSP Voorraadrapport

Laatste prijs

US$46.29

Marktkapitalisatie

US$4.0b

7D

-1.2%

1Y

-34.3%

Bijgewerkt

21 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

CRISPR Therapeutics AG

NasdaqGM:CRSP Voorraadrapport

Marktkapitalisatie: US$4.0b

CRSP Overzicht aandelen

CRISPR Therapeutics AG, een bedrijf dat zich bezighoudt met genbewerking, richt zich op de ontwikkeling van op genen gebaseerde geneesmiddelen voor ernstige menselijke ziekten met behulp van zijn platform Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-geassocieerd eiwit 9 (Cas9). Meer informatie

CRISPR Therapeutics AG Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor CRISPR Therapeutics
Historische aandelenkoersen
Huidige aandelenkoersUS$46.29
52 Week HoogtepuntUS$91.10
52 Week LaagUS$43.42
Bèta1.66
11 maand verandering-3.64%
3 maanden verandering-4.93%
1 Jaar Verandering-34.33%
33 jaar verandering-42.80%
5 jaar verandering-32.04%
Verandering sinds IPO228.53%

Recent nieuws en updates

Recent updates

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Nov 11

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Crispr Therapeutics: Poised For A Major Turnaround

Oct 28

CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Oct 02
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Sep 13

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Sep 04
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 14

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Aug 09
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 07

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Jul 13

Crispr Therapeutics: Beaten Down But Not Broken

Jul 07

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Jun 18
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 10

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Jun 03

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

May 13
Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

May 10
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

May 09

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

May 03

Crispr Therapeutics: Now Is The Time To Buy

Apr 24

Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Apr 16
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 26

There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Feb 22
There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Crispr Therapeutics: Cautiously Optimistic

Feb 22

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Feb 01

Crispr Therapeutics: Commercial Validation Is The Next Step

Jan 18

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Jan 11

CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

Dec 25
CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Nov 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Oct 05
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

Sep 14
CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Jul 24
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Jun 28
Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Apr 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 06
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

Dec 08
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag

Sep 28

Crispr: Elucidating And Forecasting Key Developments

Sep 21

Rendement voor aandeelhouders

CRSPUS BiotechsUS Markt
7D-1.2%-6.5%-1.0%
1Y-34.3%14.6%30.3%

Rendement versus industrie: CRSP presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 14.6 % opleverde.

Rendement versus markt: CRSP presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.3 % opleverde.

Prijsvolatiliteit

Is CRSP's price volatile compared to industry and market?
CRSP volatility
CRSP Average Weekly Movement6.3%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: CRSP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van CRSP is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2013407Sam Kulkarniwww.crisprtx.com

CRISPR Therapeutics AG, een bedrijf dat zich bezighoudt met genbewerking, richt zich op de ontwikkeling van op genen gebaseerde geneesmiddelen voor ernstige menselijke ziekten met behulp van zijn Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-geassocieerd eiwit 9 (Cas9)-platform. CRISPR/Cas9 is een genbewerkingstechnologie die precieze gerichte veranderingen in genomisch DNA mogelijk maakt. Het bedrijf heeft een portefeuille van therapeutische programma's in een reeks van ziektegebieden, waaronder hemoglobinopathieën, immuun-oncologie en auto-immuun, in vivo, en type 1 diabetes.

CRISPR Therapeutics AG Samenvatting

Hoe verhouden de winst en inkomsten van CRISPR Therapeutics zich tot de beurswaarde?
CRSP fundamentele statistieken
MarktkapitalisatieUS$4.03b
Inkomsten(TTM)-US$239.59m
Inkomsten(TTM)US$202.83m

19.5x

P/S-verhouding

-16.5x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CRSP resultatenrekening (TTM)
InkomstenUS$202.83m
Kosten van inkomstenUS$463.89m
Brutowinst-US$261.06m
Overige uitgaven-US$21.47m
Inkomsten-US$239.59m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-2.81
Brutomarge-128.71%
Nettowinstmarge-118.13%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde CRSP op de lange termijn?

Bekijk historische prestaties en vergelijking